Triple-negative breast cancer, or TNBC, gets its name from the absence of the three molecular targets—estrogen receptors, progesterone receptors, and HER2—that drive most other breast cancers and that have enabled effective drugs for them. Without these handles, clinicians are left with chemotherapy, and outcomes remain grim: heightened invasiveness, frequent recurrence, and poor five-year survival. Because no currently approved targeted therapy exists for TNBC, finding a vulnerability that is specific to these tumors has been a central goal of cancer research for more than a decade. The new study attacks that problem from an unusual angle: not the genome, but the phosphoproteome—the vast catalog of phosphate tags attached to proteins that switch cellular machinery on and off.

The team began with deep-coverage phosphoproteomic profiling of trace clinical specimens collected across breast cancer subtypes. This ultra-sensitive approach allowed them to compare the phosphorylation patterns of proteins in tumor tissue samples so small that conventional proteomics would fail. Out of thousands of phosphorylation events, one stood out: a phosphate group attached to serine 39, a single amino acid position on the enzyme aldolase A, or ALDOA. The modification appeared consistently in TNBC specimens but not in the other breast cancer subtypes, marking it as a candidate signature of the disease. Tissue microarray analysis of larger patient cohorts then confirmed that ALDOA S39 phosphorylation was enriched in triple-negative tumors, strengthening the link between this molecular mark and the most dangerous form of breast cancer.

ALDOA is a workhorse of glycolysis, the metabolic pathway that breaks down glucose into energy and building blocks. Cancer cells famously favor glycolysis even in the presence of oxygen—the Warburg effect—because the pathway supplies both ATP and the raw materials needed for rapid cell division. The researchers wanted to know precisely how the S39 phosphate tag changes ALDOA’s behavior. Through a series of biochemical assays, they found that the phosphorylation does not alter ALDOA’s enzymatic activity directly. Instead, it changes the protein’s fate inside the cell. Unphosphorylated ALDOA is normally flagged by TRIM25, an E3 ubiquitin ligase that attaches ubiquitin chains to proteins, sentencing them to destruction by the proteasome, the cell’s waste-disposal system. But when serine 39 is phosphorylated, this ubiquitination is attenuated. The proteasome can no longer efficiently degrade ALDOA, so the enzyme accumulates to abnormally high levels.

The consequences of this stabilization are exactly what a tumor wants. Using quantitative measurements of glucose metabolism, the team showed that cells carrying phosphorylated ALDOA took up more glucose, secreted more lactate, and produced more ATP than their counterparts. In other words, the single phosphate tag acts as a metabolic master switch, cranking up glycolytic flux and endowing TNBC cells with the energy and biosynthetic capacity they need to proliferate, invade, and metastasize. When the researchers engineered cancer cells to express an ALDOA variant that could not be phosphorylated at serine 39, glycolysis dropped and tumor growth slowed, while a phosphomimetic variant had the opposite effect. The causal chain—from phosphorylation to protein stabilization to metabolic reprogramming to malignancy—was now complete on paper.

One question remained: which kinase was attaching the phosphate in the first place? To answer it, the team turned to TurboID proximity labeling combined with mass spectrometry, a technique that biotinylates proteins in the immediate vicinity of a target so they can be identified, alongside classical co-immunoprecipitation experiments. The search converged on MINK1, a kinase belonging to the germinal center kinase family that had not previously been implicated in breast cancer metabolism. The experiments confirmed that MINK1 physically interacts with ALDOA and directly phosphorylates serine 39. In TNBC cells, MINK1 activity tracked with ALDOA stability and glycolytic output, positioning MINK1 at the top of the newly discovered signaling axis.

The translational payoff came when the researchers tested KY-05009, a selective small-molecule inhibitor of MINK1 that had been developed for other purposes. In cell culture, the drug destabilized ALDOA, restored TRIM25-mediated degradation, and choked off glycolysis. The team then escalated to increasingly realistic preclinical models: cell line-derived xenografts, in which human cancer cells are implanted in mice; patient-derived organoids, miniature tumors grown from surgically obtained patient tissue that preserve the original tumor’s biology; and patient-derived orthotopic xenografts, in which patient tissue is implanted into the mammary fat pad of mice to recapitulate the tumor’s native environment. Across all of these platforms, KY-05009 suppressed tumor growth and, importantly, reduced metastasis—the process responsible for most TNBC deaths.

The significance of this work lies in both its mechanism and its strategy. Mechanistically, it reveals a complete regulatory circuit—a kinase, a phosphorylation site, an E3 ligase, and a metabolic enzyme—that had never been assembled before. Strategically, it validates the idea that proteomics of trace clinical samples can uncover disease-specific molecular events that genomics alone would miss. Phosphorylation is a reversible, drug-accessible modification, and kinases have historically been among the most successful drug targets in oncology. By nominating MINK1 as the upstream driver of TNBC’s metabolic reprogramming, the study converts a basic biochemical discovery into a therapeutic hypothesis that can be tested with tools that already exist.

There are important caveats. The findings rest on preclinical models, and the journey from xenografts and organoids to human clinical trials is long and uncertain. KY-05009 itself would need extensive safety, pharmacokinetic, and dosing studies before it could be evaluated in patients, and the field has seen many promising kinase inhibitors fail in the clinic. The study also raises questions about how to identify patients most likely to benefit—presumably those whose tumors show high ALDOA S39 phosphorylation, a biomarker that would itself need clinical validation. Still, the prospect of a targeted metabolic therapy for TNBC, a disease where targeted options are essentially nonexistent, is a compelling one.

The research was carried out by a consortium spanning several Chinese institutions, including the Beijing Institute of Lifeomics, the Academy of Military Medical Sciences, Renmin Hospital of Wuhan University, and collaborating universities, with corresponding authors Qinong Ye and Ping Xu coordinating the effort. The work was supported by national research programs in China, including the National Natural Science Foundation of China and the CAMS Innovation Fund for Medical Sciences. As the field of cancer metabolism continues to mature, this study stands as a demonstration that the phosphoproteome—the layer of cellular regulation sitting between genes and metabolism—can yield actionable drug targets for the cancers that need them most. For patients with triple-negative breast cancer, whose treatment options have barely expanded in decades, the MINK1–ALDOA axis now represents one of the most concrete and chemically tractable leads to emerge in years.

TGF-β is a multifunctional cytokine with dual roles in cancer biology. In early tumorigenesis, it tends to act as a tumor suppressor by inhibiting cell cycle progression and promoting apoptosis. However, in established cancers like glioblastoma, TGF-β often flips the script, aiding tumor cells in evading immune surveillance, enhancing their invasive capabilities, and fostering an immunosuppressive microenvironment. This paradoxical behavior makes TGF-β a challenging but tantalizing therapeutic target. The study at hand dives deep into how natural phytochemicals—bioactive compounds derived from plants—can be leveraged to recalibrate TGF-β signaling, potentially reversing its tumor-promoting effects.

The authors meticulously explore the molecular intricacies of TGF-β signaling in glioblastoma cells, detailing how this pathway orchestrates a range of oncogenic processes. Activation of TGF-β receptors initiates a cascade involving SMAD proteins, which translocate to the nucleus and regulate gene expression, affecting cell fate decisions. Crucially, the overactivation of this pathway in glioblastoma contributes to extracellular matrix remodeling, angiogenesis, and suppression of antitumor immunity. The study connects these molecular phenomena with the clinical attributes of glioblastoma, including its notorious capacity for rapid growth, diffuse infiltration, and resistance to chemo-radiotherapy.

Phytochemicals have long been associated with health benefits, yet their role in targeting complex signaling pathways like TGF-β in malignancies is a novel frontier. This research sheds light on several phytochemical candidates capable of modulating TGF-β signaling at various junctures, effectively slowing or halting the aggressive phenotype of glioblastoma cells. Compounds such as curcumin, resveratrol, epigallocatechin gallate (EGCG), and quercetin are scrutinized for their biochemical interactions, showcasing their ability to suppress TGF-β-induced SMAD activation or enhance natural inhibitory mechanisms within the pathway.

Particularly intriguing is the study’s focus on the dual impact of these phytochemicals—not only do they inhibit tumor growth and invasion, but they also seem to tilt the immunological balance against the tumor. TGF-β is notorious for its role in establishing an immunosuppressive microenvironment by affecting regulatory T cells, natural killer cells, and tumor-associated macrophages. The phytochemicals discussed have demonstrated capabilities in restoring immune effector functions compromised by TGF-β hyperactivity, suggesting a multimodal therapeutic potential that combines tumor suppression with immune reactivation.

Beyond the cellular level, the study emphasizes the pharmacokinetic and delivery challenges faced in translating these promising phytochemicals into glioblastoma treatments. The blood-brain barrier presents a formidable obstacle, limiting the CNS bioavailability of many compounds. The article details innovative approaches to improve delivery, including nanoparticle encapsulation, conjugation with targeting ligands, and combinatorial therapies designed to synergize phytochemicals with existing standard-of-care treatments like temozolomide and radiotherapy.

The authors also address the complexity of dosing regimens and long-term safety, underscoring the necessity of rigorous clinical trials to validate the efficacy and tolerability of phytochemical-based interventions. They highlight preclinical models demonstrating the ability of these compounds to reduce tumor burden and extend survival, yet caution against over-enthusiasm until human data confirm these benefits.

Crucially, this research fills a significant gap in current oncological paradigms by positioning natural compounds not merely as complementary agents but as potential primary modulators of a critical oncogenic pathway. This repositioning sparks a renewed interest in integrating traditional herbal medicine insights with molecular oncology to craft next-generation therapies against glioblastoma.

The interplay between TGF-β signaling and tumor heterogeneity is another focal point. Glioblastomas exhibit a mosaic of cellular subpopulations, including cancer stem-like cells that are particularly resistant to therapy and adept at co-opting the TGF-β pathway to maintain their stemness and invasive potential. Phytochemicals have shown promise in targeting these robust cell subsets, which often escape eradication by conventional modalities.

Moreover, the study delves into the crosstalk between TGF-β and other signaling cascades within glioblastoma cells, such as the PI3K/AKT and MAPK pathways, illustrating how phytochemicals might exert multi-target effects. This broad-spectrum interference could dismantle the molecular networks that confer survival advantages to tumor cells, potentially overcoming resistance mechanisms.

In the context of the tumor microenvironment, the paper also details how TGF-β influences the fibrotic stroma and remodeling of the extracellular matrix, facilitating tumor cell migration and invasion into surrounding brain parenchyma. Phytochemicals with anti-fibrotic and anti-inflammatory properties may counteract these remodeling processes, limiting metastatic spread and disease progression.

Among the most compelling aspects of this research is the translational perspective it offers. By marrying traditional phytochemical knowledge with state-of-the-art molecular biology and advanced drug delivery systems, the authors pave a clear path toward novel, integrative glioblastoma therapies. The potential for these natural agents to enhance quality of life, reduce side effects, and improve overall survival creates an exciting paradigm shift for future clinical oncology.

The authors conclude with a visionary outlook, advocating for multi-disciplinary collaboration among oncologists, pharmacologists, botanists, and bioengineers to fast-track the development of phytochemical-based therapeutics. Their work not only expands the arsenal against glioblastoma but also exemplifies the power of nature-inspired solutions to address some of the most intractable challenges in cancer treatment.

This study serves as a beacon of hope and innovation, illustrating how dissecting the complexities of TGF-β signaling and harnessing the therapeutic potential of plant-derived compounds can open new frontiers in combating one of the deadliest brain cancers. As research progresses, the integration of phytochemicals into clinical protocols may well transform the glioblastoma treatment landscape, offering renewed hope for patients worldwide.

Subject of Research:

Article Title: Harnessing the role of transforming growth factor-β in glioblastoma: a focus on phytochemicals

Article References:
Nakhaei, A., Abedi, M., Afshari, S. et al. Harnessing the role of transforming growth factor-β in glioblastoma: a focus on phytochemicals. Med Oncol 42, 529 (2025). https://doi.org/10.1007/s12032-025-03090-9

Image Credits: AI Generated